{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:33:13Z","timestamp":1793745193934,"version":"4.6.1"},"reference-count":129,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007075","name":"European Society for Medical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007075","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.esmoop.2026.106888","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T08:16:54Z","timestamp":1775117814000},"page":"106888","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Uveal melanoma: ESMO\u2013EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up"],"prefix":"10.1016","volume":"11","author":[{"given":"S.","family":"Piperno-Neumann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Angi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.A.","family":"Ascierto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.F.","family":"Baurain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.C.","family":"Burgmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Cassoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.E.","family":"Coupland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Dendale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Fortuna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Gastaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Gutierrez-Miguelez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Heegaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.J.","family":"Jager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Kapiteijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Keilholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Kilic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Marinkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Moulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Nathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.P.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Pica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Piulats","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Ryll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.J.","family":"Sacco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Sauerwein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Schlaak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Stedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Valente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.M.","family":"Verdijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Verhoef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Michielin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.esmoop.2026.106888_bib1","doi-asserted-by":"crossref","first-page":"817","DOI":"10.3390\/cancers11060817","article-title":"Uveal melanoma: a european network to face the many challenges of a rare cancer","volume":"11","author":"Piperno-Neumann","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.esmoop.2026.106888_bib3","article-title":"Management of patients with rare adult solid cancers: objectives and evaluation of European reference networks (ERN) EURACAN","volume":"39","author":"Blay","year":"2024","journal-title":"Lancet Reg Health Eur"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106888_bib4","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41572-020-0158-0","article-title":"Uveal melanoma","volume":"6","author":"Jager","year":"2020","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106888_bib5","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1038\/s41467-020-16276-8","article-title":"Whole genome landscapes of uveal melanoma show an ultraviolet radiation signature in iris tumours","volume":"11","author":"Johansson","year":"2020","journal-title":"Nat Commun"},{"issue":"13","key":"10.1016\/j.esmoop.2026.106888_bib6","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1167\/iovs.64.13.45","article-title":"Worldwide incidence of ocular melanoma and correlation with pigmentation-related risk factors","volume":"64","author":"Wu","year":"2023","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106888_bib7","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.ajo.2005.05.034","article-title":"Population-based incidence of uveal melanoma in various races and ethnic groups","volume":"140","author":"Hu","year":"2005","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"10.1016\/j.esmoop.2026.106888_bib8","first-page":"918","article-title":"Uveal melanoma in young patients","volume":"118","author":"Singh","year":"2000","journal-title":"Arch Ophthalmol"},{"issue":"5","key":"10.1016\/j.esmoop.2026.106888_bib9","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0161-6420(03)00078-2","article-title":"Incidence of uveal melanoma in the United States: 1973-1997","volume":"110","author":"Singh","year":"2003","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.esmoop.2026.106888_bib10","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1001\/jamaophthalmol.2013.129","article-title":"Association of ocular and oculodermal melanocytosis with the rate of uveal melanoma metastasis: analysis of 7872 consecutive eyes","volume":"131","author":"Shields","year":"2013","journal-title":"JAMA Ophthalmol"},{"issue":"12","key":"10.1016\/j.esmoop.2026.106888_bib11","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1136\/jmedgenet-2011-100156","article-title":"Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers","volume":"48","author":"Abdel-Rahman","year":"2011","journal-title":"J Med Genet"},{"issue":"8","key":"10.1016\/j.esmoop.2026.106888_bib12","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.3390\/cancers11081114","article-title":"Families with BAP1-tumor predisposition syndrome in the Netherlands: path to identification and a proposal for genetic screening guidelines","volume":"11","author":"Chau","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106888_bib13","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/jnci\/djaa047","article-title":"Germline MBD4 mutations and predisposition to uveal melanoma","volume":"113","author":"Derrien","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106888_bib14","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S0002-9394(14)77914-0","article-title":"Modifications of Callender\u2019s classification of uveal melanoma at the Armed Forces Institute of Pathology","volume":"96","author":"McLean","year":"1983","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"10.1016\/j.esmoop.2026.106888_bib15","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.3390\/cancers11081075","article-title":"Uveal melanoma biopsy: a review","volume":"11","author":"Frizziero","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.esmoop.2026.106888_bib16","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/modpathol.2017.187","article-title":"Combined mutation and copy-number variation detection by targeted next-generation sequencing in uveal melanoma","volume":"31","author":"Smit","year":"2018","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106888_bib17","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1167\/tvst.8.2.18","article-title":"Next-generation sequencing of uveal melanoma for detection of genetic alterations predicting metastasis","volume":"8","author":"Afshar","year":"2019","journal-title":"Transl Vis Sci Technol"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106888_bib18","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.3390\/cancers12041039","article-title":"Targeted next-generation sequencing of 117 routine clinical samples provides further insights into the molecular landscape of uveal melanoma","volume":"12","author":"Thornton","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.esmoop.2026.106888_bib19","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ajo.2018.07.045","article-title":"Gene expression profiling and PRAME status versus tumor-node-metastasis staging for prognostication in uveal melanoma","volume":"195","author":"Cai","year":"2018","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106888_bib20","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1167\/iovs.10-5979","article-title":"Detection of M2-macrophages in uveal melanoma and relation with survival","volume":"52","author":"Bronkhorst","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106888_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001501","article-title":"Comprehensive analysis of cutaneous and uveal melanoma liver metastases","volume":"8","author":"Hoefsmit","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106888_bib22","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/cjp2.86","article-title":"Patterns of BAP1 protein expression provide insights into prognostic significance and the biology of uveal melanoma","volume":"4","author":"Farquhar","year":"2018","journal-title":"J Pathol Clin Res"},{"issue":"13","key":"10.1016\/j.esmoop.2026.106888_bib23","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall survival benefit with tebentafusp in metastatic uveal melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2026.106888_bib24","series-title":"AJCC Cancer Staging Manual","first-page":"813","article-title":"Uveal melanoma","author":"Kivel\u00e4","year":"2017"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106888_bib25","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1167\/iovs.14-15571","article-title":"The prognostic effect of American Joint Committee on Cancer staging and genetic status in patients with choroidal and ciliary body melanoma","volume":"56","author":"Bagger","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106888_bib26","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1159\/000520218","article-title":"Improved prognostic precision in uveal melanoma through a combined score of clinical stage and molecular prognostication","volume":"8","author":"Stacey","year":"2022","journal-title":"Ocul Oncol Pathol"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106888_bib27","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ophtha.2021.11.018","article-title":"Adding the cancer genome atlas chromosome classes to American Joint Committee on Cancer system offers more precise prognostication in uveal melanoma","volume":"129","author":"Gelmi","year":"2022","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.esmoop.2026.106888_bib28","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.preteyeres.2011.05.003","article-title":"Estimating prognosis for survival after treatment of choroidal melanoma","volume":"30","author":"Damato","year":"2011","journal-title":"Prog Retin Eye Res"},{"issue":"3","key":"10.1016\/j.esmoop.2026.106888_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0116371","article-title":"Digital PCR validates 8q dosage as prognostic tool in uveal melanoma","volume":"10","author":"Versluis","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106888_bib30","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ccell.2017.07.003","article-title":"Integrative analysis identifies four molecular and clinical subsets in uveal melanoma","volume":"32","author":"Robertson","year":"2017","journal-title":"Cancer Cell"},{"issue":"7229","key":"10.1016\/j.esmoop.2026.106888_bib31","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/nature07586","article-title":"Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi","volume":"457","author":"Van Raamsdonk","year":"2009","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.esmoop.2026.106888_bib32","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.ccell.2017.04.002","article-title":"RasGRP3 mediates MAPK pathway activation in GNAQ mutant uveal melanoma","volume":"31","author":"Chen","year":"2017","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.esmoop.2026.106888_bib33","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ccr.2014.04.016","article-title":"Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry","volume":"25","author":"Feng","year":"2014","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.esmoop.2026.106888_bib34","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/bjc.2017.259","article-title":"GNAQ and GNA11 mutations and downstream YAP activation in choroidal nevi","volume":"117","author":"Vader","year":"2017","journal-title":"Br J Cancer"},{"issue":"6009","key":"10.1016\/j.esmoop.2026.106888_bib35","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1126\/science.1194472","article-title":"Frequent mutation of BAP1 in metastasizing uveal melanomas","volume":"330","author":"Harbour","year":"2010","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.esmoop.2026.106888_bib36","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.ophtha.2016.01.023","article-title":"Uveal melanomas with SF3B1 mutations: a distinct subclass associated with late-onset metastases","volume":"123","author":"Yavuzyigitoglu","year":"2016","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106888_bib37","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1038\/s41467-018-04322-5","article-title":"Outlier response to anti-PD1 in uveal melanoma reveals germline MBD4 mutations in hypermutated tumors","volume":"9","author":"Rodrigues","year":"2018","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.esmoop.2026.106888_bib38","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1158\/1078-0432.CCR-15-2071","article-title":"PRAME as an independent biomarker for metastasis in uveal melanoma","volume":"22","author":"Field","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106888_bib39","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/eye.2012.255","article-title":"Molecular pathology of uveal melanoma","volume":"27","author":"Coupland","year":"2013","journal-title":"Eye (Lond)"},{"issue":"8","key":"10.1016\/j.esmoop.2026.106888_bib40","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1016\/j.ophtha.2012.02.017","article-title":"Collaborative Ocular Oncology Group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma","volume":"119","author":"Onken","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.esmoop.2026.106888_bib41","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2147\/OPTH.S120530","article-title":"Ocular melanoma-when you have seen one, you have not seen them all: a clinical outcome study from the Surveillance, Epidemiology and End Results (SEER) database (1973-2012)","volume":"11","author":"Mahendraraj","year":"2017","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106888_bib42","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ophtha.2015.09.014","article-title":"Local recurrence significantly increases the risk of metastatic uveal melanoma","volume":"123","year":"2016","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.esmoop.2026.106888_bib43","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1001\/archopht.119.5.670","article-title":"Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15","volume":"119","year":"2001","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.esmoop.2026.106888_bib44","series-title":"Noncutaneous Melanoma","article-title":"Uveal melanoma","author":"Grisanti","year":"2018"},{"issue":"23","key":"10.1016\/j.esmoop.2026.106888_bib45","doi-asserted-by":"crossref","first-page":"7156","DOI":"10.3390\/jcm11237156","article-title":"Local resection in choroidal melanoma: a review","volume":"11","author":"Caminal","year":"2022","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106888_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brachy.2013.11.008","article-title":"The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma","volume":"13","year":"2014","journal-title":"Brachytherapy"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106888_bib47","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.brachy.2015.12.001","article-title":"Brachytherapy vs. external beam radiotherapy for choroidal melanoma: survival and patterns-of-care analyses","volume":"15","author":"Abrams","year":"2016","journal-title":"Brachytherapy"},{"issue":"12","key":"10.1016\/j.esmoop.2026.106888_bib48","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archopht.124.12.1684","article-title":"The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report no. 28","volume":"124","year":"2006","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.esmoop.2026.106888_bib49","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.radonc.2021.11.007","article-title":"Local tumor control and treatment related toxicity after plaque brachytherapy for uveal melanoma: a systematic review and a data pooled analysis","volume":"166","author":"Buonanno","year":"2022","journal-title":"Radiother Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106888_bib50","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ijrobp.2015.01.029","article-title":"Long-term results of the UCSF-LBNL randomized trial: charged particle with helium ion versus iodine-125 plaque therapy for choroidal and ciliary body melanoma","volume":"92","author":"Mishra","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106888_bib51","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13014-024-02580-w","article-title":"Efficacy and safety of proton radiotherapy in treating choroidal melanoma: a systematic review and meta-analysis","volume":"20","author":"Miao","year":"2025","journal-title":"Radiat Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106888_bib52","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.radonc.2011.06.038","article-title":"Fractionated stereotactic radiotherapy for uveal melanoma, late clinical results","volume":"102","author":"Muller","year":"2012","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106888_bib53","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/COC.0000000000000775","article-title":"Systematic review and meta-analysis on the use of photon-based stereotactic radiosurgery versus fractionated stereotactic radiotherapy for the treatment of uveal melanoma","volume":"44","author":"Kosydar","year":"2021","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.106888_bib54","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.radonc.2021.01.030","article-title":"Local tumour control and radiation side effects for fractionated stereotactic photon beam radiotherapy compared to proton beam radiotherapy in uveal melanoma","volume":"157","author":"van Beek","year":"2021","journal-title":"Radiother Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106888_bib55","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3390\/cancers15020333","article-title":"Ocular complications of radiotherapy in uveal melanoma","volume":"15","author":"Zemba","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10.1016\/j.esmoop.2026.106888_bib56","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1097\/IAE.0000000000003105","article-title":"Eighteen-month results of intravitreal anti-vascular endothelial growth factor on vision and microcirculation in radiation maculopathy","volume":"41","author":"Eandi","year":"2021","journal-title":"Retina"},{"key":"10.1016\/j.esmoop.2026.106888_bib57","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ajo.2017.05.019","article-title":"Pattern of local recurrence after I-125 episcleral brachytherapy for uveal melanoma in a Spanish referral ocular oncology unit","volume":"180","author":"S\u00e1nchez-Tabernero","year":"2017","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106888_bib58","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0161-6420(01)00902-2","article-title":"Primary transpupillary thermotherapy for small choroidal melanoma in 256 consecutive cases: outcomes and limitations","volume":"109","author":"Shields","year":"2002","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106888_bib59","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.ajo.2015.06.017","article-title":"Local recurrence after primary proton beam therapy in uveal melanoma: risk factors, retreatment approaches, and outcome","volume":"160","author":"Seibel","year":"2015","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"10.1016\/j.esmoop.2026.106888_bib60","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.ajo.2014.07.013","article-title":"Salvage proton beam therapy in local recurrent uveal melanoma","volume":"158","author":"Riechardt","year":"2014","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"10.1016\/j.esmoop.2026.106888_bib61","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.ijrobp.2009.12.018","article-title":"Uveal melanoma recurrence after fractionated proton beam therapy: comparison of survival in patients treated with reirradiation or with enucleation","volume":"79","author":"Marucci","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3S","key":"10.1016\/j.esmoop.2026.106888_bib62","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1097\/IOP.0000000000001800","article-title":"Adjuvant external beam radiotherapy following enucleation of eyes with extraocular extension from uveal melanoma","volume":"37","author":"Roelofs","year":"2021","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"5","key":"10.1016\/j.esmoop.2026.106888_bib63","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/s41433-022-02280-3","article-title":"Post-enucleation outcomes of patients with uveal melanoma in Scotland","volume":"37","author":"Sarode","year":"2023","journal-title":"Eye (Lond)"},{"issue":"suppl 15","key":"10.1016\/j.esmoop.2026.106888_bib64","doi-asserted-by":"crossref","first-page":"9502","DOI":"10.1200\/JCO.2017.35.15_suppl.9502","article-title":"A randomized multicenter phase 3 trial of adjuvant fotemustine versus surveillance in high risk uveal melanoma (UM) patients (FOTEADJ)","volume":"35","author":"Piperno-Neumann","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.106888_bib65","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.976837","article-title":"Adjuvant crizotinib in high-risk uveal melanoma following definitive therapy","volume":"12","author":"Khan","year":"2022","journal-title":"Front Oncol"},{"issue":"16 suppl","key":"10.1016\/j.esmoop.2026.106888_bib66","doi-asserted-by":"crossref","first-page":"9509","DOI":"10.1200\/JCO.2024.42.16_suppl.9509","article-title":"Phase II multi-center study of adjuvant nivolumab in combination with ipilimumab in patients with high-risk uveal melanoma (HCRN MEL17-309)","volume":"42","author":"Rapisuwon","year":"2024","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.esmoop.2026.106888_bib67","doi-asserted-by":"crossref","first-page":"9586","DOI":"10.1200\/JCO.2022.40.16_suppl.9586","article-title":"Randomized phase II study of adjuvant sunitinib or valproic acid in high-risk patients with uveal melanoma: the final analysis of cohort 1","volume":"40","author":"Seedor","year":"2022","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.esmoop.2026.106888_bib68","doi-asserted-by":"crossref","first-page":"9510","DOI":"10.1200\/JCO.2024.42.16_suppl.9510","article-title":"A phase 2 safety and efficacy study of neoadjuvant\/adjuvant darovasertib for localized ocular melanoma","volume":"42","author":"Joshua","year":"2024","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106888_bib69","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1093\/ajcp\/aqad029","article-title":"Multiorgan involvement of dormant uveal melanoma micrometastases in postmortem tissue from patients without coexisting macrometastases","volume":"160","author":"Gill","year":"2023","journal-title":"Am J Clin Pathol"},{"issue":"31","key":"10.1016\/j.esmoop.2026.106888_bib70","doi-asserted-by":"crossref","first-page":"8076","DOI":"10.1200\/JCO.2005.02.6534","article-title":"Variates of survival in metastatic uveal melanoma","volume":"23","author":"Rietschel","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.106888_bib71","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ajo.2016.06.002","article-title":"Validation of a prognostic staging for metastatic uveal melanoma: a collaborative study of the European Ophthalmic Oncology Group","volume":"168","author":"Kivel\u00e4","year":"2016","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"10.1016\/j.esmoop.2026.106888_bib72","doi-asserted-by":"crossref","first-page":"863","DOI":"10.3390\/cancers11060863","article-title":"Development of a prognostic nomogram for liver metastasis of uveal melanoma patients selected by liver MRI","volume":"11","author":"Mariani","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.esmoop.2026.106888_bib73","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0120181","article-title":"Development and external validation of a prognostic nomogram for metastatic uveal melanoma","volume":"10","author":"Valpione","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.esmoop.2026.106888_bib74","series-title":"Cancer Regional Therapy","first-page":"323","article-title":"Regional therapies for hepatic melanoma metastases","author":"Meijer","year":"2020"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106888_bib75","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.soc.2020.09.001","article-title":"An overview of liver directed locoregional therapies","volume":"30","author":"Hoppener","year":"2021","journal-title":"Surg Oncol Clin N Am"},{"issue":"11","key":"10.1016\/j.esmoop.2026.106888_bib76","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.ejso.2009.02.016","article-title":"Surgical management of liver metastases from uveal melanoma: 16 years\u2019 experience at the Institut Curie","volume":"35","author":"Mariani","year":"2009","journal-title":"Eur J Surg Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2026.106888_bib77","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.ejso.2016.02.019","article-title":"Radiofrequency ablation and surgical resection of liver metastases from uveal melanoma","volume":"42","author":"Mariani","year":"2016","journal-title":"Eur J Surg Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2026.106888_bib78","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1093\/annonc\/mdz176","article-title":"Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study","volume":"30","author":"Khoja","year":"2019","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2026.106888_bib79","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/CMR.0000000000000575","article-title":"Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis","volume":"29","author":"Rantala","year":"2019","journal-title":"Melanoma Res"},{"issue":"6","key":"10.1016\/j.esmoop.2026.106888_bib80","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1097\/CMR.0000000000000286","article-title":"Isolated (hypoxic) hepatic perfusion with high-dose chemotherapy in patients with unresectable liver metastases of uveal melanoma: results from two experienced centres","volume":"26","author":"de Leede","year":"2016","journal-title":"Melanoma Res"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106888_bib81","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1245\/s10434-015-4968-3","article-title":"Results of a randomized controlled multicenter phase III trial of percutaneous hepatic perfusion compared with best available care for patients with melanoma liver metastases","volume":"23","author":"Hughes","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2026.106888_bib82","doi-asserted-by":"crossref","first-page":"4976","DOI":"10.1245\/s10434-025-17231-x","article-title":"An open-label, randomized study of melphalan\/hepatic delivery system versus best alternative care in patients with unresectable metastatic uveal melanoma","volume":"32","author":"Zager","year":"2025","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2026.106888_bib83","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s00270-019-02177-x","article-title":"Safety of percutaneous hepatic perfusion with melphalan in patients with unresectable liver metastases from ocular melanoma using the Delcath Systems\u2019 second-generation hemofiltration system: a prospective non-randomized phase II trial","volume":"42","author":"Meijer","year":"2019","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"17","key":"10.1016\/j.esmoop.2026.106888_bib84","first-page":"6343","article-title":"Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma metastatic to liver","volume":"9","author":"Alexander","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"16","key":"10.1016\/j.esmoop.2026.106888_bib85","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1200\/JCO.22.01705","article-title":"Isolated hepatic perfusion with melphalan for patients with isolated uveal melanoma liver metastases: a multicenter, randomized, open-label, phase III trial (the SCANDIUM trial)","volume":"41","author":"Olofsson Bagge","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106888_bib86","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/SLA.0000000000006255","article-title":"Survival and quality of life after isolated hepatic perfusion with melphalan as a treatment for uveal melanoma liver metastases: final results from the phase III randomized controlled trial SCANDIUM","volume":"282","author":"Olofsson Bagge","year":"2025","journal-title":"Ann Surg"},{"issue":"3","key":"10.1016\/j.esmoop.2026.106888_bib87","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/annonc\/mdt585","article-title":"Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial","volume":"25","author":"Leyvraz","year":"2014","journal-title":"Ann Oncol"},{"issue":"1129","key":"10.1016\/j.esmoop.2026.106888_bib88","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20210200","article-title":"Selective internal radiation therapy for hepatic metastases of uveal melanoma: a systematic review","volume":"95","author":"Alexander","year":"2022","journal-title":"Br J Radiol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106888_bib89","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1148\/radiol.2019190199","article-title":"A prospective phase II trial of radioembolization for treatment of uveal melanoma hepatic metastasis","volume":"293","author":"Gonsalves","year":"2019","journal-title":"Radiology"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106888_bib90","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ajo.2009.01.023","article-title":"Effectiveness of treatments for metastatic uveal melanoma","volume":"148","author":"Augsburger","year":"2009","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106888_bib91","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41571-022-00714-1","article-title":"Advances in the clinical management of uveal melanoma","volume":"20","author":"Carvajal","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106888_bib92","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1136\/bjophthalmol-2016-309034","article-title":"Metastatic disease from uveal melanoma: treatment options and future prospects","volume":"101","author":"Carvajal","year":"2017","journal-title":"Br J Ophthalmol"},{"issue":"10","key":"10.1016\/j.esmoop.2026.106888_bib93","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1038\/s41416-023-02199-w","article-title":"LXS196 for metastatic uveal melanoma \u2013 finally some progress","volume":"128","author":"Rodrigues","year":"2023","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.esmoop.2026.106888_bib94","doi-asserted-by":"crossref","first-page":"879","DOI":"10.3390\/ijms21030879","article-title":"The role of immune checkpoint blockade in uveal melanoma","volume":"21","author":"Wessely","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.esmoop.2026.106888_bib95","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1200\/JCO.20.00550","article-title":"Nivolumab plus ipilimumab for treatment-naive metastatic uveal melanoma: an open-label, multicenter, phase II trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402)","volume":"39","author":"Piulats","year":"2021","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2026.106888_bib96","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1200\/JCO.20.00605","article-title":"Nivolumab and ipilimumab in metastatic uveal melanoma: results from a single-arm phase II study","volume":"39","author":"Pelster","year":"2021","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.esmoop.2026.106888_bib97","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.1200\/JCO.22.02199","article-title":"First-line, fixed-duration nivolumab plus ipilimumab followed by nivolumab in clinically diverse patient populations with unresectable stage III or IV melanoma: CheckMate 401","volume":"41","author":"Dummer","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.106888_bib98","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.785231","article-title":"A one-armed phase I dose escalation trial design: personalized vaccination with IKK\u03b2-matured, RNA-loaded dendritic cells for metastatic uveal melanoma","volume":"13","author":"Koch","year":"2022","journal-title":"Front Immunol"},{"issue":"24","key":"10.1016\/j.esmoop.2026.106888_bib99","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1056\/NEJMoa2304753","article-title":"Three-year overall survival with tebentafusp in metastatic uveal melanoma","volume":"389","author":"Hassel","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106888_bib100","doi-asserted-by":"crossref","first-page":"8851","DOI":"10.1038\/s41467-024-53145-0","article-title":"Prospective assessment of circulating tumor DNA in patients with metastatic uveal melanoma treated with tebentafusp","volume":"15","author":"Rodrigues","year":"2024","journal-title":"Nat Commun"},{"issue":"13","key":"10.1016\/j.esmoop.2026.106888_bib101","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.3390\/cancers15133430","article-title":"Tebentafusp in patients with metastatic uveal melanoma: a real-life retrospective multicenter study","volume":"15","author":"Tomsitz","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.esmoop.2026.106888_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115634","article-title":"Real-life data on tebentafusp in metastatic uveal melanoma patients from four EURACAN Expert Centres","volume":"227","author":"van der Kooij","year":"2025","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.esmoop.2026.106888_bib103","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.annonc.2023.11.013","article-title":"Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis","volume":"35","author":"Piulats","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2026.106888_bib104","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102543","article-title":"Is tebentafusp superior to combined immune checkpoint blockade and other systemic treatments in metastatic uveal melanoma? A comparative efficacy analysis with population adjustment","volume":"115","author":"Petzold","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.esmoop.2026.106888_bib105","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2022.07.854","article-title":"Results from phase I dose escalation of IMC-F106C, the first PRAME \u00d7 CD3 ImmTAC bispecific protein in solid tumors","volume":"33","author":"Hamid","year":"2022","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106888_bib106","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1200\/JOP.2016.017897","article-title":"Integration of palliative care into standard oncology care: ASCO Clinical Practice Guideline update summary","volume":"13","author":"Ferrell","year":"2017","journal-title":"J Oncol Pract"},{"issue":"8","key":"10.1016\/j.esmoop.2026.106888_bib107","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1056\/NEJMoa1000678","article-title":"Early palliative care for patients with metastatic non-small-cell lung cancer","volume":"363","author":"Temel","year":"2010","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.esmoop.2026.106888_bib108","article-title":"Early palliative care for adults with advanced cancer","volume":"6","author":"Haun","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106888_bib109","doi-asserted-by":"crossref","DOI":"10.1080\/20450885.2024.2382080","article-title":"Early palliative care in metastatic uveal melanoma (early together): protocol of a prospective randomized phase III trial","volume":"11","author":"Piperno-Neumann","year":"2024","journal-title":"Melanoma Manag"},{"key":"10.1016\/j.esmoop.2026.106888_bib110","doi-asserted-by":"crossref","first-page":"382","DOI":"10.14694\/EdBook_AM.2013.33.382","article-title":"Surveillance options for patients with uveal melanoma following definitive management","author":"Francis","year":"2013","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106888_bib111","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1136\/bjophthalmol-2012-302323","article-title":"MRI in the detection of hepatic metastases from high-risk uveal melanoma: a prospective study in 188 patients","volume":"97","author":"Marshall","year":"2013","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"10.1016\/j.esmoop.2026.106888_bib112","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.jfo.2015.04.005","article-title":"Prospective study of surveillance testing for metastasis in 100 high-risk uveal melanoma patients","volume":"38","author":"Piperno-Neumann","year":"2015","journal-title":"J Fr Ophtalmol"},{"issue":"8","key":"10.1016\/j.esmoop.2026.106888_bib113","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/j.ophtha.2012.01.045","article-title":"Liver function testing is not helpful for early diagnosis of metastatic uveal melanoma","volume":"119","author":"Mouriaux","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.esmoop.2026.106888_bib114","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ajo.2020.03.049","article-title":"Hepatic ultrasonography compared with computed tomography and magnetic resonance imaging at diagnosis of metastatic uveal melanoma","volume":"216","author":"Rantala","year":"2020","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106888_bib115","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1001\/jamaophthalmol.2015.4810","article-title":"Hepatic ultrasonography for surveillance in patients with uveal melanoma","volume":"134","author":"Choudhary","year":"2016","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106888_bib116","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ejso.2009.08.010","article-title":"Preoperative staging of liver metastases from uveal melanoma by magnetic resonance imaging (MRI) and fluorodeoxyglucose-positron emission tomography (FDG-PET)","volume":"36","author":"Servois","year":"2010","journal-title":"Eur J Surg Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2026.106888_bib117","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1136\/bjophthalmol-2018-312612","article-title":"Hepatic abnormalities identified by staging MRI and accuracy of MRI of patients with uveal melanoma","volume":"103","author":"Francis","year":"2019","journal-title":"Br J Ophthalmol"},{"issue":"13","key":"10.1016\/j.esmoop.2026.106888_bib118","doi-asserted-by":"crossref","first-page":"14062","DOI":"10.1002\/cam4.6058","article-title":"Differences in glucose metabolic activity in liver metastasis separates two groups of metastatic uveal melanoma patients with different prognosis","volume":"12","author":"Del Carpio","year":"2023","journal-title":"Cancer Med"},{"issue":"7","key":"10.1016\/j.esmoop.2026.106888_bib119","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.ejso.2006.04.011","article-title":"Detection of metastatic disease in patients with uveal melanoma using positron emission tomography","volume":"32","author":"Francken","year":"2006","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106888_bib120","doi-asserted-by":"crossref","first-page":"236","DOI":"10.5301\/ejo.5000049","article-title":"Initial PET\/CT staging for choroidal melanoma: AJCC correlation and second nonocular primaries in 333 patients","volume":"22","author":"Freton","year":"2012","journal-title":"Eur J Ophthalmol"},{"issue":"8","key":"10.1016\/j.esmoop.2026.106888_bib121","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.optm.2007.03.013","article-title":"Second cancers discovered by 18FDG PET\/CT imaging for choroidal melanoma","volume":"78","author":"Chin","year":"2007","journal-title":"Optometry"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106888_bib122","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/CMR.0b013e32834d3dcb","article-title":"18F-fluorodeoxyglucose positron emission tomography\/computed tomography and magnetic resonance imaging in patients with liver metastases from uveal melanoma: results from a pilot study","volume":"22","author":"Orcurto","year":"2012","journal-title":"Melanoma Res"},{"issue":"16","key":"10.1016\/j.esmoop.2026.106888_bib123","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1016\/j.ejca.2015.07.013","article-title":"Uveal melanoma UK National Guidelines","volume":"51","author":"Nathan","year":"2015","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106888_bib124","first-page":"120","article-title":"NCCN guidelines insights: uveal melanoma, version 1.2019","volume":"18","author":"Rao","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"10.1016\/j.esmoop.2026.106888_bib126","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1037\/hea0001080","article-title":"Visual impairment and depression in uveal melanoma: optimism and pessimism as moderators","volume":"40","author":"MacDonald","year":"2021","journal-title":"Health Psychol"},{"issue":"3","key":"10.1016\/j.esmoop.2026.106888_bib127","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000502549","article-title":"Quality of life concerns in patients with uveal melanoma after initial diagnosis","volume":"6","author":"Barker","year":"2020","journal-title":"Ocul Oncol Pathol"},{"issue":"3","key":"10.1016\/j.esmoop.2026.106888_bib128","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/sj.eye.6700639","article-title":"The EORTC ophthalmic oncology quality of life questionnaire module (EORTC QLQ-OPT30). Development and pre-testing (phase I-III)","volume":"18","author":"Brandberg","year":"2004","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.esmoop.2026.106888_bib129","author":"Ryll"},{"issue":"8","key":"10.1016\/j.esmoop.2026.106888_bib130","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.annonc.2025.04.006","article-title":"ESMO-Magnitude of Clinical Benefit Scale version 2.0 (ESMO-MCBS v2.0)","volume":"36","author":"Cherny","year":"2025","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106888_bib131","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1086\/321805","volume":"33","year":"2001","journal-title":"Clin Infect Dis"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926008306?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926008306?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T15:31:54Z","timestamp":1776699114000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926008306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":129,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2059702926008306"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.106888","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Uveal melanoma: ESMO\u2013EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.106888","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"106888"}}